All the Drug Class Drugs
Non-Nucleoside Reverse Transcriptase Inhibitors. Rilpivirine 25 mg. FC Tab. 30 X 25 mg
1 tab dly with a meal
Tmt. of HIV -1 infect. in tmt. naïve adlt. ptts. in combin. with other antiretroviral.
C/I: anticonvuls.: carbamazepine, oxcarbazepine, phenobarbital, phenytoin- antimycobact.: rifampicin, rifapentine – PPI: omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole – syst. glucocortic. dexamethasone, except as a sgle. dose tmt. - St John’s wort (Hypericum perforatum).
Non-Nucleoside Reverse Transcriptase Inhibitors, Nucleoside and Nucleotide Reverse Transcriptase Inhibitors. Emtricitavine 200 mg, Rilpivirine (as HCl) 25 mg, Tenofovir Disoproxil (as Fumarate) 245 mg. F.C. TABS: 30. Adults: 1 tab dly with
meal. Under 18 yrs: Not recommend.
Over 65 yrs: use with caution. Not
recommend. in pts. with CLcr < 50 ml/
min. See lit.
Comb. of emtricitabine, tenofovir
disoproxil fumarate and rilpivirine for use
as a complete regimen for the tmt of HIV-1
infect. in adult pts with no antiretrov. tmt
hist. and with HIV-1 RNA less than or equal
to 100,000 copies/mL at the start of ther.,
and in certain virologic. suppress. (HIV-1
RNA <50 copies/mL) adult pts on a stable
antiretrov. regimen at start of ther. in order
to replace their curr. antiretrov. tmt
regimen.
C/I: Hypersens. to act. subst. or to any
excip., co-admin. with CYP3A induc. and
gastric pH incr.: anticonvuls. –
carbamazepine, oxcarbazapine,
phenobarbital, phenytoin;
antimycobacter. – rifampin, rifapentine;
PPI – dexlansoprazole, esomeprazole,
lansoprazole, omeprazole, antoprazole,
rabeprazole; glucocorticoid systemic
dexamethasone (more than a single
dose); St. John’s wort (Hypericum
perforatum).
Non-Nucleoside Reverse Transcriptase Inhibitors. Etravirine 100 mg, 200 mg. Etravirine 100 mg: TABS: 120. Adults over 18 yrs: 2 tabs 2 x dly with food.
In comb. with other antiretrovir. for tmt
HIV-1 infect. in antiretrovir. tmt-experenced
adults incl. those with non-nucleoside reverse transcriptase inhibit. (NNRTI) resist. See lit.
Etravirine 200 mg: TABS: 60. Adults over 18 yrs: 200 mg 2 x dly with food.
In comb. with other antiretrovir. for tmt
HIV-1 infect. in antiretrovir. tmt
experenced adults incl. those with NNRTI
resist. Not recommend. in comb. with N(t)
RTIs only in pts. who have experienc.
virology. fail. On an NNRTI and N(t)RTIcontai. regimen
C/I: Hypersens.
Anti HIV, Antivirals for Treatment of HIV Infections, Antivirals/HIV, Non-Nucleoside Reverse Transcriptase Inhibitors. Rilpivirine 600 mg, 900 mg. susp. for IM. inj. Prol.Rel. 2/3 ml
One 900 mg injection /mo followed by a 600 mg inj. on the next mo. Treat. may be preceded by oral rilpirivine tabs. (lead-in ther.) to assess tolerability. See full prescr. details.
In combin. with cabotegravir inject., for tmt. of human immunodefic. virus type 1 (HIV-1) infect. in adlts. who are virolog. suppress. (HIV-1 RNA < 50 copies/mL) on a stable antiretrov. regim. w/o pres. or past evid. of viral resist. to, and no prior virolog. failure with, agents of the NNRTI and INI class.
C/I: Hypersens. Not to be co-admin. with the follow. med. products, as signif. decr. in rilpivirine plasma concentr. may occur (due to CYP3A enzyme induct.), which may result in loss of its ther. effect: anticonvuls.: carbamazepine, oxcarbazepine, phenobarbital, phenytoin,
antimycobact.: rifabutin, rifampicin, rifapentine,
syst. ude of glucocorticoid dexamethasone, except as a sgle. dose tmt.,
St John’s wort (Hypericum perforatum).
Non-Nucleoside Reverse Transcriptase Inhibitors. Efavirenz 600 mg. F.C TABS: 30 x 600 mg. 600 mg 1 x dly. Children 3 yrs. and older (10-40 kg): See lit.
In combinat. with other antiretrovir.
agents for the tmt. of HIV-1 infects.
C/I: Hypersens.
Non-Nucleoside Reverse Transcriptase Inhibitors. Nevirapine (as anhydrous) 200 mg. TABS. (anhydrous): 60 x 200 mg. 1
tab×1/d for 14 days, follow. by 1
tab×2/d. in comb. with other
antiretrovir. ther.
For use in comb. with other antiretrov.
agents for the tmt. of HIV-1 infec. in
adults, adolescents, and child. of any age.
Most of the experience with Nevirapine is
in comb. with nucleoside reverse
transcriptase inhibitors (NRTIs). The
choice of a subsequent ther. after Nevirapine should be based on clinical
experience and resistance testing.
C/I: Hypersens., Readministr. to pts. who
required permanent discount. for severe
rash, rash accompanied by constitutional
sympts., hypersens. react., or clinical
hepatitis due to nevirapine, severe
hepatic impair. (Child-Pugh C) or pretreatment ASAT or ALAT > 5 ULN until
baseline ASAT/ALAT are stabilised < 5
ULN. Readministr. to pts who previous. had
ASAT or ALAT > 5 ULN during nevirapine ther. and had recur. of liver function abnormalit. upon readministr. of nevirapine, Coadministr. with herbal preparations containing St. John’s wort (Hypericum perforatum) due to risk of decreased plasma concentr. and reduced clinical effects of nevirapine.
